While medications such as methadone, buprenorphine, and naltrexone are FDA-approved for treating opioid use disorder, they ...

While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...

Lebanon Plan Commission on Monday night unanimously approved a design plan for Eli Lilly and Co.’s $4.5 billion center for advanced manufacturing and drug development at the LEAP Research and ...

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where Eli ...

In total, 234 investments creating 13,500 new jobs over the next five years, 59% of which were in regional locations ...

The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...

The 200-acre Lilly Medicine Foundry is expected to add 400 full-time jobs for highly skilled workers, including engineers, ...

In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two ...

Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...

Dealmaking in the Asia Pacific (APAC) region took off this week, with the latest showcasing Genome & Co.’s licensing deal ...

Discover the best sectors for growth stocks in the next decade. Explore which sectors may present an opportunity to bolster ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.